GlassScriptPhysician profile
Christopher Wheatley
NPI 1063969806
$886.73
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.49 · 2023: $332 · 2024: $274 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $170.74 | 2023-2025 | Rexulti, Brintellix |
| Corium, LLC | $122.23 | 2022-2025 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $93.59 | 2022-2024 | Rexulti |
| Alkermes, INC. | $82.32 | 2022-2023 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.51 | 2023-2024 | Caplyta |
| Tris Pharma INC | $58.04 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $54.41 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $43.13 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $42.88 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $42.22 | 2022-2024 | Auvelity |
| Abbvie INC. | $39.46 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.16 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $24.19 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $20.85 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wheatley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.